LOCUS

Building precision therapies with an

AI-directed, automated robotics platform

Designing Precision Medicine


We are trailblazers in the development of engineered bacteriophage products. Applying modern technologies, we are revolutionizing the treatment of bacterial infections and addressing unmet medical needs across immunology, oncology, and CNS disorders.

At our core is LOCUS, a technology stack that defines our precision products. From state-of-the-art robotics and automated biobanking to Al-driven cocktail prediction tools and cutting-edge synthetic biology techniques, we’re engineering phage cocktails with payloads that make them far more effective than their natural phage counterparts.

Learn more about how our clinical success sets us apart and how our world-class viral vector manufacturing facility produces cGMP clinical trial material at unprecedented potency and purity.

The Human Microbiome

LOCUS

Built to apply unprecedented scale to developing bacteriophage therapeutics, LOCUS is a predictive artificial intelligence and automated robotics platform that delivers optimized precision phage therapies

LBP-EC01

LBP-EC01 is an engineered bacteriophage product designed to precisely remove E. coli in patients with uncomplicated urinary tract infections (UTls)

LBP-KP01

LBP-KP01 is an engineered bacteriophage product designed to precisely remove K. pneumoniae in patients with complicated urinary tract infections (UTls)

LBP-PA01

LBP-PA01 is an engineered bacteriophage product designed to precisely remove P. aeruginosa in patients with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)

LBP-SA01

LBP-SA01 is an engineered bacteriophage product designed to precisely remove S. aureus in patients with bloodstream infections (BSIs).

LBP-AIEC01

LBP-AIEC01 is an engineered bacteriophage product designed to interrupt and alleviate the inflammatory cycle in Crohn’s disease by precisely removing adherent-invasive E. coli (AIEC)

About Us

Locus Biosciences is a precision medicine company that is developing bacteriophage-based products to precisely remove pathogenic bacteria from the human body and to leverage the microbiome to treat diseases across multiple therapeutic areas.


Our Partners

We are supported by an exceptional team of partners across academia,
government, large pharma, and investors.

Barda
Artis Ventures
Johnson & Johnson Innovation | JJDC
Tencent
NC State University
Viking
North Carolina Biotechnology Center
CARB-X